Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Clinical & Surgical Translation of Adult Stem Cells

Edward Lanphier's Biography



Edward Lanphier, CEO, Sangamo Biosciences Inc

Edward Lanphier is the founder of Sangamo BioSciences, and has served as president, chief executive officer and a member of the Board of Directors since the company’s inception in 1995. He has over 30 years of experience in the pharmaceutical and biotechnology industry including senior management positions at Somatix Therapy Corporation, BioGrowth, Inc., Biotherapeutics, Inc., and Synergen, Inc. Before joining Synergen, he was employed by Eli Lilly and Company in the strategic business planning-biotechnology group. Mr. Lanphier is currently the Chairman of the Board and Executive Committee of the Alliance for Regenerative Medicine, the preeminent global advocate for regenerative and advanced therapies. He also serves on the Board of Directors of The Biotechnology Institute, the Board of Trustees of The Buck Institute for Research on Aging, is a member of the Industry Advisory Board for the California Institute for Regenerative Medicine, and is on the Dean’s Advisory Board of the University of Michigan School of Public Health. Mr. Lanphier has a B.A. in biochemistry from Knox College.

Edward Lanphier Image

Engineering Genetic Cures: Genome Editing of Stem Cells

Monday, 9 November 2015 at 09:00

Add to Calendar ▼2015-11-09 09:00:002015-11-09 10:00:00Europe/LondonEngineering Genetic Cures: Genome Editing of Stem CellsClinical and Surgical Translation of Adult Stem Cells in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

Advances in human hematopoietic stem cell (hHSC) isolation, purification and re-engraftment combined with the ability to engineer zinc finger DNA binding protein nucleases (ZFNs) enabling the targeted and permanent modification of any investigator chosen gene sequence have combined to create therapeutic outcomes capable of generating lifelong gene tic cures.  This approach is being applied in HIV (targeted disruption of the CCR5 gene in HSCs) and in beta-thalassemia and sickle cell disease (targeted disruption of BCL11A).  However, the generality of the ZFN platform permits the target disruption and targeted gene correction of any therapeutically relevant gene thus providing a platform for engineering genetic cures through genome editing of stem cells.


Add to Calendar ▼2015-11-09 00:00:002015-11-10 00:00:00Europe/LondonClinical and Surgical Translation of Adult Stem CellsClinical and Surgical Translation of Adult Stem Cells in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com